相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Autoimmune complications of immunotherapy: pathophysiology and management
Karmela K. Chan et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo et al.
CLINICAL CANCER RESEARCH (2019)
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
Huan-huan Ji et al.
CLINICAL DRUG INVESTIGATION (2019)
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
Emanuel Raschi et al.
TARGETED ONCOLOGY (2019)
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report
Yoshitsugu Narumi et al.
BMC CANCER (2018)
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Christophoros Astaras et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2018)
CHECKPOINT INHIBITOR IMMUNE THERAPY Systemic Indications and Ophthalmic Side Effects
Lauren A. Dalvin et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
Leo L. Wang et al.
JAMA DERMATOLOGY (2018)
Immune checkpoint inhibitors and cardiovascular toxicity
Alexander R. Lyon et al.
LANCET ONCOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Immune Checkpoint Inhibitor Toxicity in 2018
Douglas B. Johnson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
Kendall F. Moseley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Clinical assessment of immune-related adverse events
Aaron Sosa et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report
Jumpei Kashima et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma
Sotaro Mori et al.
CASE REPORTS IN OPHTHALMOLOGY (2018)
Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury
F. Gelsomino et al.
ANNALS OF ONCOLOGY (2017)
Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
Omar Abdel-Rahman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
Hisato Kawakami et al.
INVESTIGATIONAL NEW DRUGS (2017)
Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies
Ayad K. Ali et al.
PHARMACOTHERAPY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature
A. Chauhan et al.
ANNALS OF ONCOLOGY (2017)
Immunology of Osteoporosis: A Mini-Review
Peter Pietschmann et al.
GERONTOLOGY (2016)
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Joelle Antoun et al.
CURRENT OPINION IN ONCOLOGY (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Corneal graft rejection in a patient treated with nivolumab for primary lung cancer
S. Le Fournis et al.
LUNG CANCER (2016)
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Acute visual loss after ipilimumab treatment for metastatic melanoma
Melissa A. Wilson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Mizuki Nishino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
FUTURE ONCOLOGY (2015)
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
IMMUNOTHERAPY (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ipilimumab-Associated Bilateral Optic Neuropathy
Oliver L. Yeh et al.
JOURNAL OF NEURO-OPHTHALMOLOGY (2015)
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Heinz Laeubli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153
Babak Baban et al.
PLOS ONE (2015)
Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
Birgitta Grundmark et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
B cells and T cells are critical for the preservation of bone hon-leostasis and attainment of peak bone mass in vivo
Yan Li et al.
BLOOD (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
分享论文
